Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors.
This webcast will feature a panel of leading experts who will engage in candid conversations about modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they will discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews will be framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions.
Welcome and Introduction
Candid Conversations About Lung Cancer: Navigating the Complex Treatment Landscape and Making Well-Informed, Individualized Clinical Decisions With Patients
- Focus on NSCLC: Latest Immunotherapies and Combinatorial Approaches
- Focus on SCLC: Immunotherapies, Combinations, and Other Emerging Treatment Strategies
- Illustrative cases in advanced and early-stage NSCLC
- Latest clinical evidence supporting the use of immunotherapies and combinations throughout the NSCLC disease continuum, and further advances on the horizon
- Real-world survey data on patient perspectives and experiences in the era of immuno-oncology
- Practicalities of treatment selection and shared decision-making in advanced and early-stage NSCLC
- Challenging cases in ES-SCLC
- State of the science on immunotherapies, combinations, and other novel therapeutic options in different settings of SCLC, and opportunities for further improvements
- Real-world survey data on patient perspectives and experiences in the context of much-needed new progress
- Practicalities of treatment selection and shared decision-making throughout the SCLC disease continuum
Summary, Reflections, and Key Takeaways
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of lung cancer.
Upon completion of this activity, participants should be better able to:
- Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC
- Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer
- Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum
- Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care
- Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer
This CME/MOC activity is jointly provided by Medical Learning Institute, Inc., GO2 Foundation for Lung Cancer, and PVI, PeerView Institute for Medical Education.
This activity is supported through educational grants from Bristol Myers Squibb, Jazz Pharmaceuticals, Inc., and Merck & Co., Inc.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc., GO2 Foundation for Lung Cancer, and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Suresh S. Ramalingam, MD, FACP, FASCO
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Hossein Borghaei, DO, MS
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Leora Horn, MD, MSc, FRCPC
Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee
The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
*Please note that if you are requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number & DOB (MM/DD). A score of 70% or higher is needed to obtain MOC credit.
Copyright © 2000-2020, PeerView